Routledge-Cavendish research in intellectual property.
"Patents, including pharmaceutical patents, enjoy extended protection for twenty years under the TRIPs Agreement. The Agreement has resulted in creating a two-tier system of the World Trade Organisation Member States, and its implementation has seen the price of pharmaceutical products skyrocket, putting essential medicines beyond the reach of the common man. The hardest hit populations come from the developing and least developed countries, that have either a weak health care system or no health care at all, where access to essential and affordable medicines is extremely difficult to achieve.Pharmaceutical Patent Protection and World Trade Law studies the problems faced by these countries in obtaining access to affordable medicines for their citizens in light of the TRIPS Agreement. It explores the opportunities that are still open for some developing countries to utilise the flexibilities available under the TRIPS Agreement in order to mitigate the damage caused by it. The book also examines the interrelationship between the world governing bodies, and the right to health contained in some of the developing countrys national constitutions."--Provided by publisher.
Formatted Contents Note
part, I Evolution of intellectual property laws, and the introduction of IP protection in the multilateral trading system / Jae Sundaram chapter 1 Introduction / Jae Sundaram chapter 2 A jurisprudential enquiry into the justification of international IP rights protection, with particular reference to pharmaceutical patents / Jae Sundaram chapter 3 Intellectual property in the multilateral trading system Forum shifting, TRIPS Agreement, Doha Declaration and TRIPS flexibilities / Jae Sundaram chapter 4 Undermining TRIPS flexibilities FTAs, RTAs, EPAs, TRIPS-plus and stoppage in transit / Jae Sundaram part, II TRIPS and developing countries Implementation, knowledge economy and IP policymaking / Jae Sundaram chapter 5 Brazil Ambitious missions and early TRIPS implementation / Jae Sundaram chapter 6 China The uneasy transition / Jae Sundaram chapter 7 India The transition from process to product patent / Jae Sundaram chapter 8 South Africa Against all odds / Jae Sundaram chapter 9 Kenya Can generics still reach the needy? / Jae Sundaram part, III TRIPS at what cost? / Jae Sundaram chapter 10 TRIPS Agreement and the future of access to affordable medicines / Jae Sundaram.